Drugs / FS120
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04648202 | Nov 2020 → Mar 2026 overdue | cancer of unknown primary site, metastatic malignant neoplasm | invoX Pharma Limited | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FS120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04648202 ↗ |
| Route | Intravenous | “Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV)” NCT04648202 ↗ |